Skip to main content
Erschienen in: Der Onkologe 1/2004

01.02.2004 | Leitthema

Raf kinases and cancer

verfasst von: Prof. Dr. U. R. Rapp, R. Schreck

Erschienen in: Die Onkologie | Sonderheft 1/2004

Einloggen, um Zugang zu erhalten

Excerpt

The Raf oncoprotein family of serine/threonine kinases comprises three members in higher vertebrates: A-Raf, B-Raf, and C-Raf. Raf kinases have been shown to play pivotal roles in the regulation of cell proliferation, differentiation, and apoptosis. They are essential components of the Ras/Raf/MEK/ERK kinase cascade, which transmits signals from activated cell surface receptors to transcription factors into the nucleus. Raf signaling pathways are often aberrantly activated in human tumors. Recently, B-Raf kinase was identified as a novel mutational and therapeutic target in human melanoma and other types of cancer. Several drugs interfering with Raf kinase signaling are currently under investigation in clinical trials. We have established a Raf-dependent transgenic mouse lung cancer model and have provided evidence that the additional loss of the p53 tumor suppressor gene in these mice accelerates tumor formation and induces a phenotypic switch. In addition, by analyzing downstream effectors of Raf kinases we have identified a connection between hypermitogenic signaling and the regulation of Polycomb group (PcG) proteins. PcG family members are known to be part of a cellular memory system that maintains transcription patterns and cell identity through cell divisions. …
Literatur
1.
Zurück zum Zitat Weinstein IB (2002) Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 297:63–64CrossRefPubMed Weinstein IB (2002) Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 297:63–64CrossRefPubMed
2.
Zurück zum Zitat Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123CrossRefPubMed Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123CrossRefPubMed
3.
Zurück zum Zitat Storm SM, Rapp UR (1993) Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67:201–210CrossRefPubMed Storm SM, Rapp UR (1993) Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67:201–210CrossRefPubMed
4.
Zurück zum Zitat Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed
5.
Zurück zum Zitat Tuveson DA, Weber BL, Herlyn M (2003) BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4:95–98CrossRefPubMed Tuveson DA, Weber BL, Herlyn M (2003) BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4:95–98CrossRefPubMed
6.
Zurück zum Zitat Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40PubMed Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40PubMed
7.
Zurück zum Zitat Houben R, Becker J, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. (submitted) Houben R, Becker J, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. (submitted)
8.
Zurück zum Zitat Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198–5202PubMed Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198–5202PubMed
9.
Zurück zum Zitat Koinuma K, Shitoh K, Miyakura Y et al. (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108:237–242CrossRefPubMed Koinuma K, Shitoh K, Miyakura Y et al. (2004) Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108:237–242CrossRefPubMed
10.
Zurück zum Zitat Rapp UR, Fensterle J, Albert S, Gotz R (2003) Raf kinases in lung tumor development. Adv Enzyme Regul 43:183–195CrossRefPubMed Rapp UR, Fensterle J, Albert S, Gotz R (2003) Raf kinases in lung tumor development. Adv Enzyme Regul 43:183–195CrossRefPubMed
11.
Zurück zum Zitat Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR (2000) Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11:185–190PubMed Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR (2000) Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11:185–190PubMed
12.
Zurück zum Zitat Fedorov LM, Tyrsin OY, Papadopoulos T, Camarero G, Gotz R, Rapp UR (2002) Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf. Cancer Res 62:6297–6303PubMed Fedorov LM, Tyrsin OY, Papadopoulos T, Camarero G, Gotz R, Rapp UR (2002) Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf. Cancer Res 62:6297–6303PubMed
13.
Zurück zum Zitat Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R, Rapp UR (2003) Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res 63:2268–2277PubMed Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R, Rapp UR (2003) Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res 63:2268–2277PubMed
14.
Zurück zum Zitat Sithanandam G, Latif F, Duh FM et al. (1996) 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol 16:868–876CrossRefPubMedPubMedCentral Sithanandam G, Latif F, Duh FM et al. (1996) 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol Cell Biol 16:868–876CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ludwig S, Engel K, Hoffmeyer A et al. (1996) 3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol 16:6687–6697CrossRefPubMedPubMedCentral Ludwig S, Engel K, Hoffmeyer A et al. (1996) 3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways. Mol Cell Biol 16:6687–6697CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Voncken JW, Neufeld B, Niessen H et al. (in revision) MAPKAP kinase 3pK phosphorylates and regulates chromatin-association of the Polycomb Group Protein Bmi1. Voncken JW, Neufeld B, Niessen H et al. (in revision) MAPKAP kinase 3pK phosphorylates and regulates chromatin-association of the Polycomb Group Protein Bmi1.
17.
Zurück zum Zitat Herrera R, Sebolt-Leopold JS (2002) Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 8: S27–31CrossRefPubMed Herrera R, Sebolt-Leopold JS (2002) Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 8: S27–31CrossRefPubMed
18.
Zurück zum Zitat Chang F, Steelman LS, Lee JT et al. (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263–1293CrossRefPubMed Chang F, Steelman LS, Lee JT et al. (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263–1293CrossRefPubMed
19.
Zurück zum Zitat Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668–675CrossRefPubMed Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668–675CrossRefPubMed
20.
Zurück zum Zitat Henry SP, Monteith D, Bennett F, Levin AA (1997) Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12:409–420PubMed Henry SP, Monteith D, Bennett F, Levin AA (1997) Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12:409–420PubMed
21.
Zurück zum Zitat Lyons JF, Wilhelm S, Hibner B, Bollag G (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219–225CrossRefPubMed Lyons JF, Wilhelm S, Hibner B, Bollag G (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219–225CrossRefPubMed
Metadaten
Titel
Raf kinases and cancer
verfasst von
Prof. Dr. U. R. Rapp
R. Schreck
Publikationsdatum
01.02.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe Sonderheft 1/2004
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-003-0649-0

Weitere Artikel der Sonderheft 1/2004

Der Onkologe 1/2004 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.